The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s law protecting 340B pricing for contract pharmacy arrangements. The two companies were also denied a preliminary injunction in Maine last week.

Judge John McConnell Jr. delivered the order from the bench. “The drug manufacturers have tested other similar state statutes through lawsuits and requests for injunctive relief based on the same or similar legal claims,” he said. “This court has reviewed the statutes, case law, the parties’ briefs, as well as amicus briefs. Based on its own reasoning and that of its sister courts, the court agrees that the plaintiffs are not likely to succeed on the merits of their claim.” 

The AHA filed amicus briefs (AbbVie, Novartis) in these cases opposing the drug companies’ motions and has opposed similar challenges by drug companies in multiple states.

Headline
 The AHA March 3 urged the Health Resources and Services Administration to take immediate action to stop a new Novo Nordisk policy from taking effect…
Headline
The Health Resources and Services Administration Feb. 25 said it will extend the deadline to April 20 to receive comments on its request for information on…
Headline
The U.S. District Court for the District of Hawaii Feb. 23 denied a preliminary injunction requested by AstraZeneca in a case challenging the state’s law…
Headline
The AHA, joined by several other national groups representing 340B hospitals, Feb. 19 urged the Health Resources and Services Administration to extend the…
Headline
The Minnesota Court of Appeals Feb. 17 affirmed a lower court decision in ruling that the state’s 340B contract pharmacy law is not preempted by federal law.…
Headline
The Department of Health and Human Services Feb. 13 issued a request for information on a new 340B rebate model program. The RFI said HHS’ Health Resources and…